The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
Sheheryar Kabraji
Nature Reviews Drug Discovery, Published online: 27 April 2026; doi:10.1038/s41573-026-01431-5 Ten years after the first FDA approval, CDK inhibition is entering a new phase in oncology. This Review examines how combination strategies, emerging CDK2- and CDK4-selective inhibitors, and developing biomarkers are reshaping the clinical use of CDK-targeted therapies and broadening their potential beyond breast cancer treatment in multiple tumour types.